Study of Bleeding With Extended Administration of an Oral Contraceptive
NCT ID: NCT00338052
Last Updated: 2008-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
207 participants
INTERVENTIONAL
2006-06-30
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Norethindrone 1 mg / ethinyl estradiol 20 mcg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 25-40
* History of regular cycles
Exclusion Criteria
* Contraindications for use of hormonal contraception
* Conditions which affect the absorption or metabolism of steroid hormones
* BMI \> 35
25 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Warner Chilcott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Warner Chilcott
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Herman Ellman, MD
Role: STUDY_DIRECTOR
Sponsor GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Warner Chilcott Investigational Site
Phoenix, Arizona, United States
Warner Chilcott Investigational Site
Phoenix, Arizona, United States
Warner Chilcott Investigational Site
Tempe, Arizona, United States
Warner Chilcott Investigational Site
Carmichael, California, United States
Warner Chilcott Investigational Site
Boynton Beach, Florida, United States
Warner Chilcott Investigational Site
Leesburg, Florida, United States
Warner Chilcott Investigational Site
Miami, Florida, United States
Warner Chilcott Investigational Site
Miami, Florida, United States
Warner Chilcott Investigational Site
West Palm Beach, Florida, United States
Warner Chilcott Investigational Site
Decatur, Georgia, United States
Warner Chilcott Investigational Site
Roswell, Georgia, United States
Warner Chilcott Investigational Site
Peoria, Illinois, United States
Warner Chilcott Investigational Site
Lexington, Kentucky, United States
Warner Chilcott Investigational Site
Louisville, Kentucky, United States
Warner Chilcott Investigational Site
New Bern, North Carolina, United States
Warner Chilcott Investigational Site
Winston-Salem, North Carolina, United States
Warner Chilcott Investigational Site
Philadelphia, Pennsylvania, United States
Warner Chilcott Investigational Site
Greenville, South Carolina, United States
Warner Chilcott Investigational Site
Pleasant Grove, Utah, United States
Warner Chilcott Investigational Site
Salt Lake City, Utah, United States
Warner Chilcott Investigational Site
Sandy City, Utah, United States
Warner Chilcott Investigational Site
Virginia Beach, Virginia, United States
Warner Chilcott Investigational Site
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR-02306
Identifier Type: -
Identifier Source: org_study_id